Long-term Observational Study of Dupilumab Effectiveness, Safety, and Patient Outcomes in Adults with Chronic Obstructive Pulmonary Disease COPD Under Real-world Conditions

What this Trial Is About

Researchers are evaluating how Dupilumab affects health-related quality of life, patient characteristics, efficacy, and safety in adults with Chronic Obstructive Pulmonary Disease COPD in a real-world setting over 24 months. This non-interventional study observes patients who have started Dupilumab treatment independently of the study, focusing on those with uncontrolled COPD despite standard inhaled therapies and elevated blood eosinophils. Patients receive Dupilumab as prescribed in routine clinical practice, with no treatment assigned by the study itself. The study collects data over two years, documenting changes in COPD symptoms, lung function, exacerbation rates, and safety outcomes as patients continue their usual care. During the study, participants clinical data, including COPD Assessment Test CAT scores, lung function tests, exacerbation frequency, and adverse events, are monitored at regular intervals up to 24 months. Patient-reported outcomes and other health measures are collected to understand Dupilumabs long-term effects in everyday use. The study also gathers information on hospitalizations, workdays missed, and reasons for treatment initiation.

Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions